Oligonucleotide API CDMO – Service Overview

Comprehensive support from oligonucleotide therapeutics research to API production with our reliable technology

Service Description

Hokkaido System Science Co., Ltd. (HSS) comprehensively supports early-stage research and development of oligonucleotide therapeutics, covering sequence design, synthesis, and gene analysis following in vitro and in vivo administration.

In addition, through a joint collaboration with Mitsubishi Gas Chemical Company, Inc. (MGC), we have established a GMP-compliant oligonucleotide manufacturing platform, enabling seamless, end-to-end support from early-stage research through to oligonucleotide API manufacturing.

CDMOサービスの流れ

Related Articles

Press Release: Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business (July 12, 2024)

Features of HSS Custom Services

1
Flexible ordering is available from spot requests to total contracts for sequence design, synthesis, and gene analysis (evaluation system).
2
Discount plans can be offered when ordering a combination of several services or an annual contract.
3
We can advise on research funding / grant proposal as a collaboration business.
A customized service plan will be proposed based on your consultation details, including schedule, budget, necessary processes, and issues.

Contact & Consultation

If you have any questions or would like to request a quote,
please feel free to contact us using the form below.

    Request

    ※ Free online consultations are available. Please indicate if required.

    Copyright © Hokkaido System Science Co.,Ltd. All rights reserved.

    Back to "Products & Services"
    Page Top